The CAV1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed to eliminate caveolin-1 (CAV1) expression in HEK293T cells. This loss-of-function model preserves polyclonal heterogeneity, enabling robust study of CAV1-dependent membrane organization, endocytosis, and signal transduction without clonal selection artifacts.
HEK293T is an extensively characterized human embryonic kidney epithelial line stably expressing SV40 large T antigen, prized for high transfection efficiency and protein yield. The polyclonal knockout format ensures diverse CAV1 disruption across the population, minimizing clonal biases and facilitating integration into transfection, viral transduction, and pharmacological screening workflows.
Caveolin-1 serves as the principal structural component of caveolae, plasma membrane invaginations that coordinate endocytosis, cholesterol homeostasis, and signal transduction. Through its caveolin-scaffolding domain, CAV1 directly binds and modulates the activity of key signaling molecules, including eNOS, SRC, HRAS, EGFR, and integrin beta1. CAV1 expression is transcriptionally upregulated by SREBP and PPARG in response to lipid status, and by TGF-beta during fibrotic signaling. Post-translational modification by SRC and PKC regulates its stability and interaction with Cavin-1, cholesterol, and heterotrimeric G-proteins, which are essential for caveolar assembly. CAV1 acts as a signaling hub: it integrates TGF-beta and Wnt pathway inputs to regulate focal adhesion turnover and mitogenic signaling via ERK and AKT. Disruption of this network impacts eNOS activation, SRC-mediated migration, and integrin-dependent mechanotransduction.
In the HEK293T background, CAV1 knockout abolishes caveolar invaginations, leading to aberrant lipid raft organization, altered endocytic trafficking, and defective mechanosensing. This model is instrumental for probing CAV1??s dichotomous roles??as a tumor suppressor in some contexts and a metastasis promoter in others??with direct relevance to carcinomas and sarcomas. It further enables studies of CAV1-linked cardiovascular abnormalities, such as impaired eNOS-driven vasodilation, and pulmonary fibrosis, where TGF-beta?CCAV1 crosstalk drives fibroblast activation. The absence of CAV1 permits unambiguous complementation with wild-type or mutant constructs to dissect isoform-specific functions.
Key applications encompass caveolae-specific uptake assays to quantify caveolae-mediated endocytosis, migration and invasion assays for metastatic potential, and phospho-signaling analysis of eNOS and ERK to evaluate cardiovascular and oncogenic pathways. Co-immunoprecipitation and lipid raft isolation facilitate mapping of CAV1 interactomes and membrane microdomain composition. Standard validation relies on Western blotting and immunofluorescence to confirm knockout efficiency and downstream effector expression. This CAV1 knockout cell population provides a robust system for mechanistic investigations and therapeutic targeting in oncology, cardiovascular biology, and fibrotic diseases. For additional information, contact Ascent Research.
